REV 5901 Property

Boiling point:

497.7±35.0 °C(Predicted)

Density 

1.123±0.06 g/cm3(Predicted)

storage temp. 

Room temperature

solubility 

≤100mg/ml in ethanol;100mg/ml in methanol;100mg/ml in acetone;100mg/ml in DMSO;100mg/ml in etonitrile.

form 

Off-white to tan solid.

pka

14.48±0.20(Predicted)

Safety

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

REV 5901 Chemical Properties,Usage,Production

Description

REV 5901 is an antagonist of cysteinyl-leukotriene receptors with a K_i value of 0.7 μM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC₅₀ value of 0.12 μM.

Uses

REV 5901 is an antagonist of cysteinyl-leukotriene receptors with a Ki value of 0.7 μM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC50 value of 0.12 μM.

Uses

L-655,238 is a potent and selective inhibitor of FLAP (5-LO-activating protein).

Definition

ChEBI: 1-[3-(2-quinolinylmethoxy)phenyl]-1-hexanol is a member of quinolines.

in vitro

previous in-vitro showed that rev 5901 had a ki value of 0.7 μm vs. [3h]leukotriene d4 ([3h]-ltd4) binding to membranes from guinea pig lung. against ltc4-, ltd4- and lte4-induced contractions of guinea pig parenchymal strips, rev 5901 had kb values of ca 3 μm and was relatively ineffective against contractions that was induced by other spasmogens. moreover, in isolated guinea pig hearts, the peptiodoleukotriene-antagonist activity was also observed against the hemodynamic and vasoconstriction effects of ltd4. in addition, unlike other reported antagonists, rev 5901 was found to be ineffective against the multiple forms of cyclic nucleotide phosphodiesterases [1].

in vivo

animal study found that the oral antagonist activity had been shown with an ltd4-induced bronchoconstriction model and with an ltd4-induced wheal response model in guinea pigs [1].

References

[1] van inwegen, r. g.,khandwala, a.,gordon, r., et al. rev 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. journal of pharmacology and experimental therapeutics 241, 117-124 (1987).